Steven Cohen’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.07M Buy
+28,900
New +$6.27M 0.01% 1527
2026
Q1
Sell
-20,000
Closed -$3.65M 3779
2025
Q4
$3.65M Buy
20,000
+5,900
+42% +$824K ﹤0.01% 2062
2025
Q3
$1.71M Hold
14,100
﹤0.01% 1503
2025
Q2
$1.47M Buy
14,100
+200
+1% +$21.2K ﹤0.01% 1424
2025
Q1
$1.62M Sell
13,900
-700
-5% -$79.7K ﹤0.01% 1307
2024
Q4
$1.24M Buy
14,600
+1,700
+13% +$156K ﹤0.01% 1414
2024
Q3
$1.16M Hold
12,900
﹤0.01% 1366
2024
Q2
$1.04M Buy
12,900
+6,100
+90% +$452K ﹤0.01% 1263
2024
Q1
$543K Buy
+6,800
New +$571K ﹤0.01% 1626

Other funds holding AXSM

Steven Cohen's AXSM Position: Q2 2026 in Review

Steven Cohen reduced its Axsome Therapeutics (AXSM) stake by 1.9% in Q2 2026, selling an estimated $1.79M and leaving 416,516 shares worth $102M. The position accounts for 0.11% of the portfolio, ranked #199.

Steven Cohen first reported a position in AXSM in Q4 2018 and has held it in 24 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Steven Cohen held 416,516 shares of Axsome Therapeutics worth $102M as of Q2 2026.
  • Steven Cohen sold 8,234 Axsome Therapeutics shares in Q2 2026, an estimated $1.79M.
  • Axsome Therapeutics made up 0.11% of Steven Cohen's portfolio in Q2 2026, its #199 holding.
  • Steven Cohen first reported a position in Axsome Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.